Patents

Literature

Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.

32 results about "Synthetase kinase" patented technology

Filter

Efficacy Topic

Property

Owner

Technical Advancement

Application Domain

Technology Topic

Technology Field Word

Patent Country/Region

Patent Type

Patent Status

Application Year

Inventor

Inhibitors of glycogen synthase kinase 3

InactiveUS7037918B2BiocideNervous disorderActive agentImmunodeficiency

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Inhibitors of glycogen synthase kinase 3

Inhibitors of glycogen synthase kinase 3

Inhibitors of glycogen synthase kinase 3

Owner:CHIRON CORP

Inhibitors of glycogen synthase kinase 3

InactiveUS7045519B2BiocideOrganic chemistryActive agentImmunodeficiency

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Inhibitors of glycogen synthase kinase 3

Inhibitors of glycogen synthase kinase 3

Inhibitors of glycogen synthase kinase 3

Owner:CHIRON CORP

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

ActiveUS20120077840A1Use of compositionPrevention and/or treatmentBiocideSenses disorderTreatment useGlycogen synthase

The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Pyrazine based inhibitors of glycogen synthase kinase 3

InactiveUS6949547B2Inhibitory activityBiocideNervous disorderPyrazineActive agent

New bicyclic based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Pyrazine based inhibitors of glycogen synthase kinase 3

Pyrazine based inhibitors of glycogen synthase kinase 3

Pyrazine based inhibitors of glycogen synthase kinase 3

Owner:CHIRON CORP

Inhibitors of glycogen synthase kinase 3

InactiveUS7425557B2BiocideOrganic chemistryActive agentImmunodeficiency

New pyridine-based compounds of Formula I, compositions, and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3-mediated disorders in vivo are provided. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Inhibitors of glycogen synthase kinase 3

Inhibitors of glycogen synthase kinase 3

Inhibitors of glycogen synthase kinase 3

Owner:NOVARTIS VACCINES & DIAGNOSTICS INC

High-efficiency non-integrated human iPSC induction platform

ActiveCN104673741AImprove induction efficiencyEasy to separateVertebrate cellsArtificial cell constructsAdenosineSomatic cell

The invention discloses a high-efficiency non-integrated human iPSC induction platform which comprises a composition, wherein the composition is used for inducing a human cell into iPSC, and the composition comprises a previous inducer and a later inducer; the previous inducer comprises the following active components: a transforming growth factor beta inhibitor, a glycogen synthetase kinase 3 inhibitor, a cAMP agonist, an S-adenosyl homocysteine hydrolase inhibitor and a p21 activated kinase inhibitor; and the later inducer comprises the following active components: the glycogen synthetase kinase 3 inhibitor, a selective ATP noncompetitive MEK inhibitor and the S-adenosyl homocysteine hydrolase inhibitor. The high-efficiency non-integrated human iPSC induction platform disclosed by the invention achieves the previous induction efficiency of the iPSC of 6.4% under the action of a previous inducer composition, can achieve the induction of a full culture of 20.8% through later induction culture or be used for totally further inducing a previous inductor clone into a human iPSC clone approaching to ESC and is far higher than the prior art in induction efficiency; in addition, the obtained iPSC is high in maturity, free of being inserted with an exogenous gene, is more approaching to the ESC in cell morphology and property and has the advantages of good stability and great high application value.

High-efficiency non-integrated human iPSC induction platform

High-efficiency non-integrated human iPSC induction platform

High-efficiency non-integrated human iPSC induction platform

Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE

3,4-dihydrobenzo[f][1,4]thiazepine compound or salts of same and medical use of same

InactiveCN101891706AInhibitory activityOrganic active ingredientsNervous disorderDiseaseDiabetes mellitus

The invention relates to 3,4-dihydrobenzo[f][1,4]thiazepine compound of the general formula I or salts of the same and medicinal use of the same, belonging to the field of pharmaceutical chemistry. The 3,4-dihydrobenzo[f][1,4]thiazepine compound can inhibit glycogen synthase kinase-3beta (GSK-3beta) and be used as the non-ATP competitive micromolecular inhibitor of the GSK-3beta to prepare medicaments used for preventing or treating diseases related to the GSK-3beta. The invention further discloses the application of a medical combination formed by the compound and pharmaceutically acceptablesalts of the same to preparation of medicaments for preventing or treating the diseases related to the GSK-3beta, such as diabetes, Alzheimer's diseases and tumors.

3,4-dihydrobenzo[f][1,4]thiazepine compound or salts of same and medical use of same

3,4-dihydrobenzo[f][1,4]thiazepine compound or salts of same and medical use of same

3,4-dihydrobenzo[f][1,4]thiazepine compound or salts of same and medical use of same

Owner:FUDAN UNIV

Culture method of vascular endothelial progenitor cells

ActiveCN105062957AExcellent self-renewal abilityAvoid uncertaintyVertebrate cellsArtificial cell constructsProgenitorSodium bicarbonate

The invention discloses a culture method of vascular endothelial progenitor cells, which comprises the following steps: 1) inducing differentiation of multipotent stem cells in a culture medium A to form mesendoderm precursor cells; and 2) inducing differentiation of the mesendoderm precursor cells in a culture medium B to form the vascular endothelial progenitor cells. The culture medium A contains a DMEM (dulbecco's modified eagle medium) culture medium, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, activin A, a bone formation protein 4 and a glycogen synthetase kinase-3 inhibitor. The culture medium B contains a DMEM culture medium, an F12 culture medium, vitamin C, insulin, a vascular endothelial growth factor and a transforming growth factor beta signal pathway inhibitor. The culture media used in the culture method do not contain any animal-derived component, and can provide sufficient nutrient substances and stable living environments for the cultured cells, thereby efficiently inducing the differentiation of the human multipotent stem cells to form the vascular-grid vascular endothelial progenitor cells which are highly similar to the human cord vessel endothelial cells.

Culture method of vascular endothelial progenitor cells

Culture method of vascular endothelial progenitor cells

Culture method of vascular endothelial progenitor cells

Owner:宁波医诺生物技术有限公司

Pyrrole based inhibitors of glycogen synthase kinase 3

InactiveUS7250443B2BiocideNervous disorderActive agentImmunodeficiency

New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Pyrrole based inhibitors of glycogen synthase kinase 3

Pyrrole based inhibitors of glycogen synthase kinase 3

Pyrrole based inhibitors of glycogen synthase kinase 3

Owner:NOVARTIS VACCINES & DIAGNOSTICS INC

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

ActiveUS8318793B2Prevention and/or treatmentUse of compositionBiocideSenses disorderGlycogen synthase ITreatment use

The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

InactiveCN101735211AOrganic active ingredientsNervous disorderDiabetes mellitusDisease

The invention belongs to the field of pharmaceutical chemistry, and discloses 2,3-dihydro[1,5] benzothiazepine compounds of non-adenosine triphosphate (ATP) competitive inhibition glycogen synthase kinase-3beta (GSK-3beta) with a structure shown in formula I. The compounds can inhibit the activity of the GSK-3beta in a non ATP competitive mode, and can be used as micromolecule inhibitors of the GSK-3beta for preparing medicines for preventing or treating GSK-3beta related diseases. The invention further provides applications of the compounds, pharmaceutical acceptable salts thereof, or medicine compositions thereof to preventing or treating the GSK-3beta related diseases. The GSK-3beta related diseases can be diabetes and an Alzheimer's disease.

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

Owner:FUDAN UNIV

Wheat glycogen synthetase kinase gene

InactiveCN1523110ASugar derivativesMicrobiological testing/measurementEscherichia coliOpen reading frame

The present invention relates to a wheat glycogen synthetase kinase gene obtained by utilizing cDNA-AFLP technique to clone the salt-stressed specific expression fragment of wheat salt-tolerant mutant, adopting sequence determinatio Blast identification and RACE method. The total length of said gene is 1573bp, in which its open reading frame (ORF) contains 1143 bp, coding 381 amino acids, its coded protein extensively participates in plant response reaction to drought, ABA induction and light induction, specially participates in salt-stressed signal conduction process. After said gene is cloned into prokaryotic expression vector, it can express out a prokaryotic expression product whose molecular weight is 43.6 KD in the colibacillus, i.e. glycogen synthetase kinase protein. Said invention also provides its application field.

Wheat glycogen synthetase kinase gene

Wheat glycogen synthetase kinase gene

Wheat glycogen synthetase kinase gene

Owner:HEBEI NORMAL UNIV

Drug for nerve regeneration

InactiveCN1774265AOrganic active ingredientsNervous disorderCerebral paralysisCerebrovascular disorder

An object of the present invention is to provide a nerve regeneration drug, a neuron regeneration promoter of neural stem cells, a neuron obtained by culturing neural stem cells in the presence of the neuron regeneration promoter, and a method for producing the neuron. In order to achieve this object, the present invention provides a nerve regeneration drug containing a substance that inhibits the activity of glycogen synthase kinase-3 as an active ingredient, a neural stem cell neuron regeneration promoter containing the substance as an active ingredient, and A neuron obtained by culturing neural stem cells in the presence of a neuron regeneration promoting agent and a method for producing the neuron. Medicine of the present invention can be used as Parkinson's disease, Alzheimer's disease, Down's syndrome, cerebrovascular disorder, cerebral apoplexy, spinal cord injury, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis It is used in the treatment of neurological diseases such as neurological disorders, epilepsy, anxiety disorders, complex disorders, depression, and bipolar disorder.

Drug for nerve regeneration

Drug for nerve regeneration

Drug for nerve regeneration

Owner:KYOWA HAKKO KOGYO CO LTD

4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3)

InactiveUS7056939B2Selective inhibiting effectImprove bioavailabilityOrganic active ingredientsBiocideGlycogen synthase IKinase

The present invention relates to a new compound of formula I as a free base or a pharmaceutically acceptable salt thereof, a process for the preparation, pharmaceutical formulations containing said therapeutically active compound and to the use of said compound in therapy.

4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3)

4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3)

4-(4Methoxybenzyl)-n′-(5-nitro1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3 (gsk3)

Owner:ASTRAZENECA AB

Inhibitors of glycogen synthase kinase 3

InactiveCN1312807ANervous disorderOrganic chemistryActive agentDepressant

New pyrimidine or pyridine based compounds, having the structure(I), compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder immunodeficiency or cancer.

Inhibitors of glycogen synthase kinase 3

Owner:CHIRON CORP

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

ActiveUS9266855B2Prevention and/or treatmentUse of compositionBiocideSenses disorderGlycogen synthase ITreatment use

The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease

InactiveUS20120077813A1InhibitionImprove bioavailabilityOrganic active ingredientsSenses disorderDiseaseHydrogen

The present invention relates to a new compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.

Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease

Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease

Imidazole Substituted Pyrimidines Useful in the Treatment of Glycogen Synthase Kinase-3 Related Disorders such as Alzheimer's Disease

Owner:ASTRAZENECA AB

Bicyclic inhibitors of glycogen synthase kinase 3

InactiveCN1434824AOrganic active ingredientsNervous disorderActive agentDepressant

Bicyclic based compounds of the formula (I), compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and a treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Owner:CHIRON CORP

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

InactiveUS20120172376A1Use of compositionPrevention and/or treatmentBiocideSenses disorderMedical disorderMedicine

The present invention relates to novel heterocyclic compounds of formula Iwherein the variables are as defined in the claims or the description,which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3β, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3β activity using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

ActiveUS20110003810A1Use of compositionPrevention and/or treatmentBiocideSenses disorderTreatment useGlycogen synthase

The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Synthesis method of glycogen synthase kinase-3 inhibitor for treating plasmodium falciparum causing malaria

InactiveCN107987090AEasy to operateShorten the production cycleOrganic chemistryAntiparasitic agentsCyclopenteneSynthesis methods

The invention discloses a synthesis technology of a glycogen synthase kinase-3 inhibitor for treating plasmodium falciparum causing malaria. The synthesis method has the advantages of simple operationand short production period, and can massively prepare the glycogen synthase kinase-3 inhibitor, namely 3-amino-4-(2-chloromethyl)-6,7-dihydro-5H-cyclopentene[b]thieno[3,2-e]pyridine-2-ylphenyl ketone.

Synthesis method of glycogen synthase kinase-3 inhibitor for treating plasmodium falciparum causing malaria

Synthesis method of glycogen synthase kinase-3 inhibitor for treating plasmodium falciparum causing malaria

Synthesis method of glycogen synthase kinase-3 inhibitor for treating plasmodium falciparum causing malaria

Owner:杨文思

Pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing glycogen synthase kinase-3 beta inhibitor as active ingredient, and functional health food composition

InactiveUS20160058738A1Easy to useUse of compositionBiocideAnimal repellantsForkhead box L2Glycogen synthase I

A pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing, as an active ingredient, one selected from the group consisting of a compound represented by chemical formula 1, a pharmaceutically acceptable salt of the compound represented by chemical formula 1, a compound represented by chemical formula 2, and a pharmaceutically acceptable salt of the compound represented by chemical formula 2, or a functional health food composition. The composition inhibits glycogen synthase kinase-3 beta (GSK3beta) and thus has an effect of inhibiting a phosphorylation of a serine, which is the 33rd amino acid of the forkhead box L2 (FOXL2) protein.

Pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing glycogen synthase kinase-3 beta inhibitor as active ingredient, and functional health food composition

Pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing glycogen synthase kinase-3 beta inhibitor as active ingredient, and functional health food composition

Pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing glycogen synthase kinase-3 beta inhibitor as active ingredient, and functional health food composition

Owner:CHUNG ANG UNIV IND ACADEMIC COOP FOUND

Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

ActiveCN112684186BEasy to acceptImprove accuracyBiological testingGlycogen synthase IBiomarker (medicine)

The invention relates to the field of medicine, and discloses a group of biomarkers, kits and applications for predicting the risk of MCI in type 2 diabetes patients. The biomarkers include optic neurin, glycogen synthase kinase-3β, and Ser9-phosphorylated glycogen synthase kinase-3β. The increase of this biomarker can evaluate MCI, which has the characteristics of high accuracy, fast detection speed, low cost, less trauma, and easy acceptance by patients. It provides a scientific and effective early prediction scheme for the occurrence of MCI in patients with type 2 diabetes. The kit can screen for MCI in a wide range of people, and only needs to collect peripheral blood to complete the detection, making it possible to screen for a wide range of elderly population.

Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

Biomarkers and kits for predicting the risk of MCI in patients with type 2 diabetes and their application

Owner:HUAZHONG UNIV OF SCI & TECH

Culture method of vascular endothelial cell progenitor cells

ActiveCN105062957BExcellent self-renewal abilityAvoid uncertaintyVertebrate cellsArtificial cell constructsSodium bicarbonateProgenitor

The invention discloses a culture method of vascular endothelial progenitor cells, which comprises the following steps: 1) inducing differentiation of multipotent stem cells in a culture medium A to form mesendoderm precursor cells; and 2) inducing differentiation of the mesendoderm precursor cells in a culture medium B to form the vascular endothelial progenitor cells. The culture medium A contains a DMEM (dulbecco's modified eagle medium) culture medium, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, activin A, a bone formation protein 4 and a glycogen synthetase kinase-3 inhibitor. The culture medium B contains a DMEM culture medium, an F12 culture medium, vitamin C, insulin, a vascular endothelial growth factor and a transforming growth factor beta signal pathway inhibitor. The culture media used in the culture method do not contain any animal-derived component, and can provide sufficient nutrient substances and stable living environments for the cultured cells, thereby efficiently inducing the differentiation of the human multipotent stem cells to form the vascular-grid vascular endothelial progenitor cells which are highly similar to the human cord vessel endothelial cells.

Culture method of vascular endothelial cell progenitor cells

Culture method of vascular endothelial cell progenitor cells

Culture method of vascular endothelial cell progenitor cells

Owner:宁波医诺生物技术有限公司

2,3-dihydrobenzazapine*compound or its salt and its medical application

ActiveCN103214431BHas inhibitory effectNo obvious inhibitory effectOrganic active ingredientsNervous disorderDiseasePancreas Cancers

The invention belongs to the pharmaceutical chemistry field, and relates to a 2,3-dihydrobenzazapine*compound with a structure shown in a formula I, the 2,3-dihydrobenzazapine*compound is capable of inhibiting glycogen synthase kinase-3beta(GSK-3beta), and is a small-molecule inhibitor of GSK-3beta, a non ATP competition effect mode is taken for inhibiting the activity of GSK-3beta, no obvious inhibition effect is provided on the tested various protein kinase, and the 2,3-dihydrobenzazapine*compound has high kinases selectivity, and can be used for preparing medicines for preventing or treating the diseases due to GSK-3beta abnormity. The invention further comprises an application of a pharmaceutically acceptable salt or a pharmaceutical composition of the compound for preventing or treating the relative diseases to GSK-3beta, the relative diseases to GSK-3beta are diabetes, Alzheimer's disease, stomach cancer, colorectal cancer, pancreas cancer, liver cancer or mixed acute leukemia, but the relative diseases are not limited by the above diseases.

2,3-dihydrobenzazapine*compound or its salt and its medical application

2,3-dihydrobenzazapine*compound or its salt and its medical application

2,3-dihydrobenzazapine*compound or its salt and its medical application

Owner:FUDAN UNIV

Polypeptide for inhibiting glycogen synthase kinase-3[beta] acetylation, coding gene of polypeptide and application of polypeptide and coding gene

ActiveCN113736760AEasy to shapeFunction increasePolypeptide with localisation/targeting motifNervous disorderKinase bindingGlycogen synthase I

The invention relates to the technical field of genetic engineering, and discloses a polypeptide for inhibiting glycogen synthase kinase-3[beta] acetylation, and a coding gene of polypeptide and application of polypeptide and coding gene. The sequence of the polypeptide is shown as SEQ.ID.NO:1. The polypeptide for inhibiting glycogen synthase kinase-3[beta] acetylation can block the combination of tau protein and glycogen synthase kinase-3[beta] in the whole level of cells and animals, and can block the acetylation and activation effects of the tau protein on the glycogen synthase kinase-3[beta]; and the morphology and function of cells are improved, and the learning and memory ability of mice is improved. The polypeptide provided by the invention can play a role in preventing and treating glycogen synthase kinase-3[beta] activation related diseases such as Alzheimer's disease and the like.

Polypeptide for inhibiting glycogen synthase kinase-3[beta] acetylation, coding gene of polypeptide and application of polypeptide and coding gene

Polypeptide for inhibiting glycogen synthase kinase-3[beta] acetylation, coding gene of polypeptide and application of polypeptide and coding gene

Polypeptide for inhibiting glycogen synthase kinase-3[beta] acetylation, coding gene of polypeptide and application of polypeptide and coding gene

Owner:HUAZHONG UNIV OF SCI & TECH

Biomarker and kit for predicting MCI risk of type 2 diabetes patients and application thereof

ActiveCN112684186AEasy to acceptImprove accuracyBiological testingEarly predictionGlycogen synthase I

The invention relates to the field of medicines, and discloses a group of biomarkers and a kit for predicting MCI risk of type 2 diabetes patients and application thereof. The biomarkers comprise optic nerve protein, glycogen synthase kinase-3beta and Ser9-phosphorylated glycogen synthase kinase-3beta. The rise of the biomarkers can evaluate MCI, and the biomarkers have the characteristics of high accuracy, high detection speed, low cost, small trauma and easy acceptance by patients, and provide a scientific and effective early prediction scheme for MCI of type 2 diabetes patients. The kit can be used for screening MCI in a large range of people, and detection can be completed only by collecting peripheral blood, so that large-range elderly population screening becomes possible.

Biomarker and kit for predicting MCI risk of type 2 diabetes patients and application thereof

Biomarker and kit for predicting MCI risk of type 2 diabetes patients and application thereof

Biomarker and kit for predicting MCI risk of type 2 diabetes patients and application thereof

Owner:HUAZHONG UNIV OF SCI & TECH

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

InactiveCN101735211BHas inhibitory effectOrganic active ingredientsNervous disorderDiseaseDiabetes mellitus

The invention belongs to the field of pharmaceutical chemistry, and discloses 2,3-dihydro[1,5] benzothiazepine compounds of non-adenosine triphosphate (ATP) competitive inhibition glycogen synthase kinase-3beta (GSK-3beta) with a structure shown in formula I. The compounds can inhibit the activity of the GSK-3beta in a non ATP competitive mode, and can be used as micromolecule inhibitors of the GSK-3beta for preparing medicines for preventing or treating GSK-3beta related diseases. The invention further provides applications of the compounds, pharmaceutical acceptable salts thereof, or medicine compositions thereof to preventing or treating the GSK-3beta related diseases. The GSK-3beta related diseases can be diabetes and an Alzheimer's disease.

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

Applications of 2,3-dihydro[1,5] benzothiazepine compounds or salts thereof in preparation of GSK-3beta inhibitor

Owner:FUDAN UNIV

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

InactiveUS10100048B2Prevention and/or treatmentUse of compositionSenses disorderNervous disorderTreatment useGlycogen synthase

The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

Owner:ABBVIE DEUTSHLAND GMBH & CO KG

Atriplex canescens glycogen synthetase kinase 3 gene clone and its application

InactiveCN104371986AImprove stress resistanceFungiTransferasesAgricultural scienceNucleotide

The invention relates to an Atriplex canescens glycogen synthetase kinase gene clone and its application, and belongs to the technical field of plant gene engineering. A plant resistance related protein AcGSK3 is a protein composed of an amino acid sequence represented by SEQ ID NO:2 in a sequence table; and the coding sequence of the coding gene AcGSK3 of the plant resistance related protein AcGSK3 is one of a coding sequence with the nucleotide sequence represented by 346-684th deoxynucleotides at 5'-terminal of an amino acid sequence represented by SEQ ID NO:1 in the sequence table, and a nucleotide molecule for coding the protein sequence of the SEQ ID NO:2 in the sequence table. The invention also relates to a recombinant expression vector containing the coding gene AcGSK3 of the plant resistance related protein AcGSK3, and a recombinant bacterium containing the coding gene AcGSK3 of the plant resistance related protein AcGSK3. A result of qRT-PCR detection of the original plant Atriplex canescens shows that the gene improves the expression under NaCl and PEG stress. AcGSK3 is introduced into Saccharomyces cerevisiae to obtain transgenic Saccharomyces cerevisiae, and stress treatment is carried out, so the result shows that the AcGSK3 can improve the drought (sorbitol) and salt (NaCl) resistance of yeast.

Atriplex canescens glycogen synthetase kinase 3 gene clone and its application

Atriplex canescens glycogen synthetase kinase 3 gene clone and its application

Atriplex canescens glycogen synthetase kinase 3 gene clone and its application

Owner:JILIN UNIV

Popular searches

Essential hypertension Brain traumas Disease cause Disease injury Cancer Bipolar mood disorder Atherosclerotic cardiovascular disease Obesity Ischemia Degenerative disease

Who we serve

R&D Engineer
R&D Manager
IP Professional

Why Patsnap Eureka

Industry Leading Data Capabilities
Powerful AI technology
Patent DNA Extraction

Social media

Patsnap Eureka Blog

PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com